SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn's Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc.

Benzinga · 08/26/2020 11:13

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced it has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic. CERC-002 is a first-in-class fully human anti-LIGHT (TNFSF14) monoclonal antibody currently being developed as a treatment for severe pediatric onset Crohn’s disease as well as in a placebo-controlled proof-of-concept trial evaluating the safety and efficacy in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome (ARDS).

The open-label, dose-escalating, signal-finding Phase 1b clinical study is designed to assess the safety, tolerability, and short-term efficacy of CERC-002 in adult subjects with moderate-to-severe Crohn’s disease who have previously failed treatment with anti-TNF agents. The Company expects to announce topline data in the first quarter of 2021.